Skip to content

Advertisement

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry

  • Radek Lakomy1,
  • Alexandr Poprach1,
  • Zbynek Bortlicek2,
  • Bohuslav Melichar3,
  • Renata Chloupkova2,
  • Rostislav Vyzula1,
  • Milada Zemanova4,
  • Katerina Kopeckova5,
  • Marek Svoboda1,
  • Ondrej Slaby1,
  • Igor Kiss1,
  • Hana Studentova3,
  • Jaroslav Juracek1,
  • Ondrej Fiala6,
  • Jindrich Kopecky7,
  • Jindrich Finek6,
  • Ladislav Dusek2,
  • Karel Hejduk2 and
  • Tomas Buchler8Email authorView ORCID ID profile
Contributed equally
BMC Cancer201717:880

https://doi.org/10.1186/s12885-017-3901-5

Received: 21 November 2016

Accepted: 8 December 2017

Published: 21 December 2017

Back to article

Open Peer Review reports

Pre-publication versions of this article are available by contacting info@biomedcentral.com.

Original Submission
21 Nov 2016 Submitted Original manuscript
4 Apr 2017 Reviewed Reviewer Report - Pablo Maroto
5 Jul 2017 Reviewed Reviewer Report - Frede Donskov
8 Oct 2017 Author responded Author comments - Radek Lakomy
Resubmission - Version 2
8 Oct 2017 Submitted Manuscript version 2
13 Nov 2017 Reviewed Reviewer Report - Frede Donskov
2 Dec 2017 Author responded Author comments - Radek Lakomy
Resubmission - Version 3
2 Dec 2017 Submitted Manuscript version 3
Publishing
8 Dec 2017 Editorially accepted
21 Dec 2017 Article published 10.1186/s12885-017-3901-5

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting info@biomedcentral.com.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic
(2)
Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
(3)
Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic
(4)
Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
(5)
Department of Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
(6)
Department of Oncology, Charles University and University Hospital, Pilsen, Czech Republic
(7)
Department of Oncology, Hradec Králové University Hospital and Faculty of Medicine, Charles University, Hradec Králové, Hradec Králové, Czech Republic
(8)
Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic

Advertisement